Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120924 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,009
- Enrollment target
NCT02120924 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 1,009 participants.
The verdict
NCT02120924, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,009 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.
Interventions
- DRUG Vehicle
- DRUG Azelaic acid
- DRUG Finacea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,009 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120924
The ClinicalTrials.gov registry entry for NCT02120924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,009 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT02120924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120924 about?
NCT02120924 is a clinical study titled "A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea". The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.
What is the current status of trial NCT02120924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,009 participants. The study started on 2013-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02120924?
The interventions under investigation include: Vehicle (DRUG), Azelaic acid (DRUG), Finacea (DRUG).
Who is sponsoring clinical trial NCT02120924?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.